In recent developments in cancer therapy, specific inhibitors, such as tazemetostat, which targets enhancer of zeste homolog 2 (EZH2) and thereby mediates histone H3 lysine (K) 27 methylation, have been approved by the Food and Drug Administration (FDA) for the treatment of follicular lymphoma and are currently in use. Here, EZH2 is linked to follicular lymphoma.